Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DAWN NASDAQ:EPRX NASDAQ:NAGE NASDAQ:VIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDAWNDay One Biopharmaceuticals$7.41-0.8%$6.86$5.64▼$16.76$765.17M-1.251.20 million shs567,537 shsEPRXEupraxia Pharmaceuticals$5.270.0%$5.36$2.20▼$6.20$189.51M1.512,228 shs5,481 shsNAGENiagen Bioscience$9.38-0.7%$10.20$3.16▼$14.69$753.66M2.21808,145 shs574,102 shsVIRVir Biotechnology$5.24+1.0%$5.10$4.16▼$14.45$720.98M1.281.52 million shs736,121 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDAWNDay One Biopharmaceuticals-0.80%+0.14%+21.48%+9.78%-47.82%EPRXEupraxia Pharmaceuticals-0.04%-2.62%+0.15%+34.05%+111.57%NAGENiagen Bioscience-0.74%-5.06%-3.60%-33.33%+181.68%VIRVir Biotechnology+0.96%+4.80%+21.86%-0.19%-32.99%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDAWNDay One Biopharmaceuticals$7.41-0.8%$6.86$5.64▼$16.76$765.17M-1.251.20 million shs567,537 shsEPRXEupraxia Pharmaceuticals$5.270.0%$5.36$2.20▼$6.20$189.51M1.512,228 shs5,481 shsNAGENiagen Bioscience$9.38-0.7%$10.20$3.16▼$14.69$753.66M2.21808,145 shs574,102 shsVIRVir Biotechnology$5.24+1.0%$5.10$4.16▼$14.45$720.98M1.281.52 million shs736,121 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDAWNDay One Biopharmaceuticals-0.80%+0.14%+21.48%+9.78%-47.82%EPRXEupraxia Pharmaceuticals-0.04%-2.62%+0.15%+34.05%+111.57%NAGENiagen Bioscience-0.74%-5.06%-3.60%-33.33%+181.68%VIRVir Biotechnology+0.96%+4.80%+21.86%-0.19%-32.99%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDAWNDay One Biopharmaceuticals 3.13Buy$25.29241.24% UpsideEPRXEupraxia Pharmaceuticals 3.17Buy$11.00108.81% UpsideNAGENiagen Bioscience 3.00Buy$13.4243.07% UpsideVIRVir Biotechnology 2.90Moderate Buy$26.80411.45% UpsideCurrent Analyst Ratings BreakdownLatest EPRX, NAGE, DAWN, and VIR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025VIRVir BiotechnologyEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$12.008/27/2025VIRVir BiotechnologyBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$12.00 ➝ $14.008/20/2025EPRXEupraxia PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.008/18/2025DAWNDay One BiopharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$25.008/11/2025NAGENiagen BioscienceHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$11.00 ➝ $12.008/6/2025DAWNDay One BiopharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$18.00 ➝ $16.008/6/2025DAWNDay One BiopharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$36.00 ➝ $25.007/24/2025EPRXEupraxia PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$11.007/11/2025VIRVir BiotechnologyRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform7/11/2025VIRVir BiotechnologyRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy$12.006/26/2025EPRXEupraxia PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDAWNDay One Biopharmaceuticals$131.16M5.79N/AN/A$4.99 per share1.48EPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/AN/ANAGENiagen Bioscience$99.60M7.51$0.06 per share159.77$0.60 per share15.63VIRVir Biotechnology$74.21M9.81N/AN/A$8.35 per share0.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDAWNDay One Biopharmaceuticals-$95.50M-$0.95N/AN/AN/A-50.63%-19.01%-16.99%10/29/2025 (Estimated)EPRXEupraxia Pharmaceuticals-$25.50M-$0.85N/AN/AN/AN/A-626.84%-118.31%11/6/2025 (Estimated)NAGENiagen Bioscience$8.55M$0.2144.67∞N/A15.24%23.12%15.53%N/AVIRVir Biotechnology-$521.96M-$4.00N/AN/AN/A-2,895.94%-50.22%-40.78%10/30/2025 (Estimated)Latest EPRX, NAGE, DAWN, and VIR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025EPRXEupraxia Pharmaceuticals-$0.21-$0.26-$0.05-$0.26N/AN/A8/6/2025Q2 2025NAGENiagen Bioscience$0.02$0.04+$0.02$0.04$28.55 million$31.12 million8/6/2025Q2 2025VIRVir Biotechnology-$0.72-$0.80-$0.08-$0.80$2.38 million$1.21 million8/5/2025Q2 2025DAWNDay One Biopharmaceuticals-$0.35-$0.29+$0.06-$0.29$35.55 million$33.91 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/AEPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/ANAGENiagen BioscienceN/AN/AN/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDAWNDay One BiopharmaceuticalsN/A9.659.53EPRXEupraxia PharmaceuticalsN/A8.728.72NAGENiagen BioscienceN/A3.883.24VIRVir BiotechnologyN/A7.017.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDAWNDay One Biopharmaceuticals87.95%EPRXEupraxia PharmaceuticalsN/ANAGENiagen Bioscience15.41%VIRVir Biotechnology65.32%Insider OwnershipCompanyInsider OwnershipDAWNDay One Biopharmaceuticals6.20%EPRXEupraxia PharmaceuticalsN/ANAGENiagen Bioscience9.39%VIRVir Biotechnology16.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDAWNDay One Biopharmaceuticals60102.43 million96.08 millionOptionableEPRXEupraxia Pharmaceuticals2935.96 millionN/AN/ANAGENiagen Bioscience12079.75 million72.26 millionN/AVIRVir Biotechnology580138.92 million116.69 millionOptionableEPRX, NAGE, DAWN, and VIR HeadlinesRecent News About These Companies84,398 Shares in Vir Biotechnology, Inc. $VIR Purchased by Cinctive Capital Management LPSeptember 8 at 5:47 AM | marketbeat.comVir Biotechnology (NASDAQ:VIR) Trading Down 6% on Insider SellingSeptember 6, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Now Covered by Analysts at Evercore ISISeptember 6, 2025 | americanbankingnews.comVicki Sato Sells 22,000 Shares of Vir Biotechnology (NASDAQ:VIR) StockSeptember 5, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Stock Price Up 8% - Here's WhySeptember 5, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Now Covered by Evercore ISISeptember 5, 2025 | marketbeat.comADAR1 Capital Management LLC Purchases 185,933 Shares of Vir Biotechnology, Inc. $VIRSeptember 4, 2025 | marketbeat.comBaker BROS. Advisors LP Sells 542,000 Shares of Vir Biotechnology, Inc. $VIRSeptember 4, 2025 | marketbeat.comEvercore ISI Group Initiates Coverage of Vir Biotechnology (VIR) with Outperform RecommendationSeptember 3, 2025 | msn.comThe Play On Vir BiotechnologySeptember 3, 2025 | seekingalpha.comVir Biotechnology initiated with an Outperform at Evercore ISISeptember 3, 2025 | msn.comVir Biotechnology, Inc. $VIR Shares Bought by Russell Investments Group Ltd.September 2, 2025 | marketbeat.comWalleye Capital LLC Sells 183,494 Shares of Vir Biotechnology, Inc. $VIRSeptember 1, 2025 | marketbeat.comNuveen LLC Takes $2.32 Million Position in Vir Biotechnology, Inc. $VIRSeptember 1, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Shares Gap Up Following Analyst UpgradeAugust 29, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Rating Increased to Buy at Bank of AmericaAugust 29, 2025 | marketbeat.comVir Biotechnology stock soars after BofA upgrade, $14 targetAugust 28, 2025 | investing.comVir Stock Soars After BofA Boosts Rating on Liver TherapyAugust 28, 2025 | finance.yahoo.comVir upgraded at BoA on potential for liver disease asset; shares surge 13%August 28, 2025 | msn.comVir Biotechnology, Inc. $VIR Shares Bought by Charles Schwab Investment Management Inc.August 28, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Rating of "Moderate Buy" by BrokeragesAugust 28, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 2025Buffett’s Cash Hoard Signals Market Caution, Value Plays EmergeBy Gabriel Osorio-Mazilli | August 19, 20253 Big Dividend Plays With Strong Earnings to Back ThemBy Nathan Reiff | August 11, 2025Why Sprouts Farmers Market is Buying $1 Billion of Its Own StockBy Gabriel Osorio-Mazilli | August 25, 2025Brinker Serves Up Earnings Beat, Sidesteps Cost PressuresBy Chris Markoch | August 14, 2025EPRX, NAGE, DAWN, and VIR Company DescriptionsDay One Biopharmaceuticals NASDAQ:DAWN$7.41 -0.06 (-0.80%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$7.33 -0.08 (-1.13%) As of 09/9/2025 05:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Eupraxia Pharmaceuticals NASDAQ:EPRX$5.27 0.00 (-0.04%) Closing price 09/9/2025 03:59 PM EasternExtended Trading$5.29 +0.03 (+0.49%) As of 09/9/2025 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.Niagen Bioscience NASDAQ:NAGE$9.38 -0.07 (-0.74%) As of 09/9/2025 04:00 PM EasternNiagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.Vir Biotechnology NASDAQ:VIR$5.24 +0.05 (+0.96%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$5.14 -0.11 (-2.00%) As of 09/9/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing The Quiet Before the Catalyst: Vertical Aerospace's Next Move Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
